Original medicines
Pharmasyntez Group
Contributing to the nation’s health through innovation
We turn scientific advances into modern medicines
- 4
original medicines on the market
- 1
medicine undergoing registration
- 14
medicine in development
A focus on original medicines
The full innovation journey — from development to clinical practice
.webp&w=3840&q=90)
- 001
Fundamental research
An original medicine is the result of painstaking research and years of work by hundreds of scientists
- 002
Evidence base
The medicine’s efficacy and safety are supported by clinical trials and the accumulated evidence base
- 003
Technological superiority
Our proprietary research-intensive technologies ensure the purity of pharmaceutical ingredients and consistent results in every unit of product
Pharmasyntez Group’s achievements
Innovative approaches to treatment
Seroguard
For the prevention and treatment of adhesion formation associated with surgery. Patent protection for the medicine is being sought in 140 countries worldwide
Perchlozone
.webp&w=3840&q=90)
For the treatment of pulmonary tuberculosis, including multidrug-resistant tuberculosis. Patent protection is being sought in 77 countries worldwide
Sibcordia
Indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP) who are resistant to or intolerant of prior therapy, including imatinib, or who have the T315I mutation in the BCR::ABL1 gene
Saterex
The medicine is indicated for the treatment of type 2 diabetes mellitus in adult patients over 18 years of age (in combination with dietary therapy and exercise)
Nexaglif
A sodium—glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus